SkinHealth Q3 Sales Slip 2.1% to $69.2M, Adjusted EBITDA Jumps to $13.4M
SKIN is trading near its 52-week low of $9.68 (6.9% above the low).
Summary
SkinHealth's Q3 sales fell 2.1% to $69.2 million, but adjusted EBITDA rose to $13.4 million and the net loss shrank to $(0.9) million. The company retired its remaining $103.2 million of 2026 Notes and issued updated FY2026 guidance of $281-$287 million in sales and $48-$50 million in adjusted EBITDA.
Key Events · Earnings and Guidance · SKIN
-
Q3 Sales Down 2.1% to $69.2M
Net sales were $69.2 million versus $70.7 million a year ago, driven by delivery systems falling to $18.8 million from $20.8 million; consumables grew to $50.4 million from $49.8 million.
-
Adjusted EBITDA Nearly Doubles
Adjusted EBITDA rose to $13.4 million (19.3% margin) from $8.9 million, and the net loss narrowed to $(0.9) million from $(11.0) million, with gross margin up to 68.2% from 64.6%.
-
2026 Notes Retired, Cash Falls
The company repaid the remaining $103.2 million principal of its 2026 Notes on September 30, 2026, leaving cash and equivalents of $112.4 million versus $232.7 million at year-end 2025.
-
FY2026 Guidance Set at $281-$287M Sales
Updated guidance calls for net sales of $281-$287 million and adjusted EBITDA of $48-$50 million, reflecting continued sales pressure and cost discipline.
Analysis · SKIN · Industrial Applications And Services
Revenue is still shrinking, but the profit picture flipped hard: adjusted EBITDA nearly doubled to $13.4 million and the net loss narrowed to $(0.9) million from $(11.0) million a year ago, helped by a 68.2% gross margin and lower operating spend. The company also retired its remaining $103.2 million of 2026 Notes, cutting cash to $112.4 million but clearing the debt overhang that had threatened a $353 million repurchase obligation. The updated full-year guide of $281-$287 million in sales and $48-$50 million in adjusted EBITDA is the number that matters now, because it tells investors whether the cost cuts are outrunning the revenue decline.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKIN was trading at $10.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $9.68 to $34.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.